Page 1 of 1

'improvements never seen before'

Posted: Tue May 22, 2012 10:04 am
by Cece
http://ccsvi-ms.ning.com/profiles/blogs ... g-for-high
I have to say that the operators at The Clinics of the Heart are Interventional Cardiologists and this is our most extreme experience looking improvements never seen before with any previous endovascular treatment for cardiovascular diseases, including the coronary intervention.
The interventionalists at this Mexican clinic have not seen the degree of improvements that we show, in their patients for other diseases.

The reason for symptom improvement is logical in that outflow obstructions of blood flow from any organ are damaging to that organ. It will take time and money and efforts for our researchers to prove this but it would be shocking for the outcome not to be in our favor. The hard part is waiting and knowing that our researchers are underfunded in a somewhat hostile environment and that there are established financial interests in the MS market.

The name 'liberation procedure' and 'liberation therapy' are used in the media and in the FDA alert. This makes it seem very alternative but it is garden-variety angioplasty. Angioplasty of outflow obstructions in the major veins that drain the brain and spinal cord. And it is not the veins themselves that are narrowed, but outflow obstructions within the veins, most commonly the valves at the base of the jugular near the collarbone.

We all know this, but I like to repeat it from time to time, because every day there must be someone who has newly heard about CCSVI, and I would like everyone to know the most accurate truth as we can establish it through research and personal experiences of our own and others.

One of my major objections to the FDA alert is that it labels angioplasty of the jugulars to be experimental. Angioplasty of the jugulars is done commonly for central venous stenoses such as thrombosis, in particular in dialysis patients. This is not as rare or as unsafe or as alternative as might be believed.

Re: 'improvements never seen before'

Posted: Tue May 29, 2012 10:20 pm
by Tracker
Why have stents never been needed in Thrombosis cases of the jugular veins?

Re: 'improvements never seen before'

Posted: Wed May 30, 2012 2:02 am
by jean-la-grenouille
Hi Tracker ! I think stents are still not very safe to be used in the IJV. Risk of thrombosis, clotting, migation...it depends of the venous obstruction and the physicians....

Thank you Cece for reminding us in a synthetic way, what we know about MS and CCSVI.
Business applied to science, leads to conflicts of interest and nonsense.

Re: 'improvements never seen before'

Posted: Wed May 30, 2012 3:45 am
by Cece
We're talking about stents in dialysis-related jugular thrombosis or non-CCSVI related cases of central venous stenosis?
I don't know if they are or aren't ever used. Let's see...
http://www.uptodate.com/contents/use-of ... lar-access
The role of the endoluminal stent in the management of venous stenosis of dialysis access is unclear. Although stents can help manage some access difficulties, they are sometimes inappropriately utilized. Stents are not permanent solutions. With the exception of the Flair™ Endovascular Stent Graft (C. R. Bard, Inc.; Tempe, AZ), they are not FDA approved for dialysis vascular access use. In addition, they add significant cost and a new set of possible complications.

The clinician should therefore be very selective in the use of stents for the treatment of stenotic dialysis access. Stent placement is justified only when its use will clearly result in one or more of the following benefits:

•Extends access life
•Saves an otherwise failed access
•Avoids surgery

Although a stent can improve the appearance of a lesion, it is unclear if these devices provide benefits and long-term outcomes that justify their increased cost and potential complications. Angioplasty alone should therefore be used as the primary treatment modality for all venous lesions. (See "Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts".)

Primary patency rates following the venous use of stents have been relatively poor, being approximately 20 percent at one year [1-3]. However, with aggressive reintervention, the cumulative patency rate is approximately 70 percent at one year.